SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
S-8	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
3	Aug 5, 2026	Aug 5, 2026	View filing
SC 13G	Aug 3, 2026	Aug 3, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
3	Jul 30, 2026	Jul 30, 2026	View filing
SC 13G	Jul 27, 2026	Jul 27, 2026	View filing
8-K	Jul 27, 2026	Jul 27, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
DEFA14A	Apr 30, 2026	Apr 30, 2026	View filing

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

South San Francisco, CA

69 employees

www.cytomx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sean A. McCarthy

View full financials